QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies

QIAGEN to Market Test That Shows if Prostate Cancer Is Responding to Two Therapies
QIAGEN will begin marketing a test that Johns Hopkins University developed to detect whether advanced prostate cancer patients are failing to respond to the widely used therapies Zytiga (enzalutamide) and Xtandi (abiraterone). If doctors know that a prostate cancer patient is resistant to the drugs, they can develop a more tailored treatment. The test, called AdnaTest Prostate Cancer Panel AR-V7, will detect that resistance. In to the test being used in treatment, researchers can use it to help select patients for clinical trials. Prostate cancer is the third leading cause of cancer death among American men. Zytiga and Xtandi are hormone therapies for patients with castration-resistant prostate cancer (CRPC). They block the androgen receptor signaling that is essential to the cancer's growth. Although they represent breakthroughs in metastatic CRPC treatment, 20 to 40 percent of patients fail to respond to them, however. Johns Hopkins researchers discovered that prostate cancer patients who lacked an androgen receptor variation known as AR-V7 survive longer than those with the variation. The study, “AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer,” was published in the New England Journal of Medicine in 2014. The researchers also discovered that the variation, which lacks a portion of the full androgen receptor, was associated with resistance to Zytiga and Xtandi. The drugs failed to block androgen receptor signaling, allowing prostate cancer cells to keep growing. Thirty-one of the patients in the study received Zytiga and 31 Xtandi. The results were clea
Subscribe or to access all post and page content.